Previous 10 | Next 10 |
home / stock / otlk / otlk articles
ISELIN, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA app...
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday. Lipella Pharmaceuticals Inc. (NASDA...
Gainers SeaStar Medical Holding Corporation (NASDAQ: ICU) shares climbed 36.4% to $1.0516. SeaStar medical shares jumped 70% on Wednesday after t...
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreeme...
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The P...
ISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA ap...
ATLANTA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Outlook Therapeutics, Inc. ("Outlook Therapeutics"...
ISELIN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA ap...
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 89.5% to $2.7852 after the company reported outcomes from a UroShield study conducted at t...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
2024-07-16 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...